Open Orphan PLC - Contract signed with Carna Bioscience
("Open Orphan" or the "Company")
Open Orphan signs contract with Carna Bioscience
Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the signing of a contract with Carna Bioscience ("Carna") (www.carnabio.com)for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for the Company over the next twelve months. Carna is a Japanese company specialising in kinase biology, developing innovative treatments against cancer and immune disorders.
This contract sees
This new contract builds upon several years of existing work between Venn and Carna during which both parties closely collaborated on drug development planning and pre-clinical activities services contracts.
The contract is further evidence of Open Orphan's strategy to secure long-term partnership contracts which deliver recurring revenues for the business by working in close collaboration with high quality customers.
"This contract is further evidence of delivering against one of Open Orphan's key objectives, transforming Venn. The contract is an exciting one as we are now providing a much broader range of pharmaceutical services and the Venn team have managed to transition the provision of its initial pre-clinical consultancy services to Carna into a formal Phase 1 Clinical Trial. We look forward to delivering the contract for Carna Bioscience and I look forward to announcing more positive news in due course."
Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900
Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363
Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Notes to Editors on Open Orphan:
Notes to Editors on Carna Biosciences Inc:
Carna Biosciences is a biopharmaceutical company focused on the discovery and development of kinase inhibitor drugs to treat serious unmet medical needs in oncology, autoimmune and neurological diseases by inhibiting kinases that are important drivers for those diseases. Carna Biosciences was founded in
This information is provided by RNS, the news service of the
Quick facts: Open Orphan PLC
Market Cap: £97.84 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE